After completing her undergraduate degree in Biological Sciences at the University of Oxford, Ruth completed her PhD at Cambridge in Developmental Genetics in 2002. She then joined the Cambridge spin-out Daniolabs Ltd, becoming a Senior Research Associate and staying with the company from its inception in 2002 to its sale to Summit Plc in 2007. Ruth then spent two years as a consultant at PharmaVentures, where she focussed on commercial projects such as licensing, valuations (including ENPVs and benchmarking), deal analysis, fund raising assistance, due diligence and business plan assessment, primary/secondary research and competitive landscape analysis. As part of PharmaVentures’ Transactions team, Ruth was intimately involved with two successful, multi-million dollar divestments of API manufacturing businesses, from the Dow Chemical Company and Helsinn Healthcare. Ruth joined Oxford University Innovation as a Technology Transfer Manager in August 2009.